Details for Patent: 7,569,610

Title:	Modified release formulations of a bupropion salt
Abstract:	The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s):	Oberegger; Werner (Mississauga, CA), Maes; Paul (Toronto, CA), Saleh; Mohammad Ashty (Oakville, CA)
Assignee:	Biovail Laboratories International SRL (St. Michael, BB)
Filing Date:	May 22, 2007
Application Number:	11/751,768
Claims:	1. A method of treating depression, comprising administering an effective amount of bupropion hydrobromide to treat depression to a subject in need thereof. 2. The method according to claim 1, wherein said method is a method of treating cognitive symptoms in depression, bipolar depression, post partum depression, minor depression, lack of energy in depression, or suicidal depression comprising administering an effective amount of bupropion hydrobromide to treat cognitive symptoms in depression, bipolar depression, post partum depression, minor depression, lack of energy in depression, or suicidal depression to a subject in need thereof. 3. The method according to claim 1, wherein said method comprises administration of a once-daily dosage of bupropion hydrobromide. 4. The method according to claim 2, wherein said method comprises administration of a once-daily dosage of bupropion hydrobromide. 5. The method according to according to claim 1, wherein the bupropion hydrobromide has greater stability measured by less degradation products compared to bupropion hydrochloride.